Bethesda, MD, United States of America

Resat Cinar

USPTO Granted Patents = 7 


 

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Resat Cinar: Innovator in Cannabinoid Therapeutics

Introduction

Resat Cinar, an inventive mind based in Bethesda, MD, has made significant contributions to the field of cannabinoid research with a total of seven granted patents. His work focuses on developing novel therapeutic compounds that interact with cannabinoid receptors, paving the way for new treatments and therapies.

Latest Patents

Among his latest patents, Resat Cinar has developed compounds comprising a cannabinoid receptor mediating scaffold that is conjugated to a second therapeutic scaffold. This innovative approach holds potential for advancing the efficacy and versatility of cannabinoid-based treatments in various medical applications.

Career Highlights

Resat is affiliated with the United States Department of Health and Human Services, where he continues his research and development efforts in cannabinoid therapeutics. Through his dedication and innovation, he has established himself as a prominent figure in the research community.

Collaborations

Throughout his career, Resat has collaborated with esteemed colleagues such as George Kunos and Malliga R. Iyer. Their collective expertise and teamwork contribute to advancing understanding and applications of cannabinoid receptor systems.

Conclusion

In summary, Resat Cinar's innovative work in cannabinoid receptor mediating compounds showcases his commitment to addressing medical challenges through scientific research. His seven patents not only reflect his creativity as an inventor but also signify potential advancements in therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…